{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:48:32Z","timestamp":1753883312718,"version":"3.41.2"},"reference-count":38,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Brain and Neuroscience Advances"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p> Teriflunomide is an oral disease-modifying therapy for relapsing\u2013remitting multiple sclerosis patients. A decline in physical and cognitive functions, which negatively impacts their quality of life (QoL), is observed in relapsing\u2013remitting multiple sclerosis patients. The aim of this study was to characterise adult Portuguese relapsing\u2013remitting multiple sclerosis patients treated with teriflunomide in routine clinical practice concerning their quality of life, comorbidities, treatment effectiveness, satisfaction, compliance and safety. TeriLIVE-QoL was a multicentre, non-interventional, prospective cohort study that collected demographic and clinical characteristics, patient-reported outcomes and adverse events from patients treated with teriflunomide of 14 mg over 2 years. Notably, around 18 months of this period occurred during the COVID-19 pandemic. Of the 99 participants, 25% were treatment-na\u00efve. Annualised relapse rate and the score for the Hospital Anxiety and Depression Scale decreased after 1 (p = 0.01) and 2 years of treatment (p &lt; 0.001), respectively. Convenience (p = 0.001), effectiveness (p = 0.002) and global satisfaction scores (p &lt; 0.001) presented high values (up to 95.6) and continued to improve along the study. Treatment persistence was 77%, and compliance reached 82% 2 years after initiation. Three patients experienced serious adverse events. TeriLIVE-QoL provides real-world evidence of clinical effectiveness, high treatment satisfaction, consistent safety and improved psychiatric outcomes, associated with elevated treatment persistence and compliance in patients treated with teriflunomide.iance reached 82% 2 years after initiation. Three patients experienced serious adverse events. <\/jats:p>","DOI":"10.1177\/23982128231185290","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T10:59:37Z","timestamp":1689937177000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Teriflunomide treatment outcomes in multiple sclerosis: A Portuguese real-life experience"],"prefix":"10.1177","volume":"7","author":[{"given":"Carla Cec\u00edlia","family":"Nunes","sequence":"first","affiliation":[{"name":"Centro Hospitalar e Universit\u00e1rio de Coimbra (CHUC), Coimbra, Portugal"}]},{"given":"Pedro","family":"Abreu","sequence":"additional","affiliation":[{"name":"Departamento de Neuroci\u00eancias Cl\u00ednicas e Sa\u00fade Mental, Faculdade de Medicina, Universidade do Porto, Porto, Portugal"},{"name":"Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o (CHUSJ), Porto, Portugal"}]},{"given":"Filipe","family":"Correia","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de Matosinhos (ULSM) \u2013 Hospital Pedro Hispano, Matosinhos, Portugal"}]},{"given":"Irene","family":"Mendes","sequence":"additional","affiliation":[{"name":"Hospital Garcia de Orta, Almada, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1409-0831","authenticated-orcid":false,"given":"Ana Martins da","family":"Silva","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio de Santo Ant\u00f3nio (CHUdSA), Porto, Portugal"}]}],"member":"179","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"bibr1-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-13-138"},{"key":"bibr2-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103774"},{"key":"bibr3-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-2-12"},{"key":"bibr4-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0212-x"},{"key":"bibr5-23982128231185290","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2014-057"},{"volume-title":"Statistical Power Analysis for the Behavioral Sciences","year":"1988","author":"Cohen J","key":"bibr6-23982128231185290"},{"key":"bibr7-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512436594"},{"key":"bibr8-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70308-9"},{"key":"bibr9-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.07.006"},{"key":"bibr10-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210417"},{"key":"bibr11-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1451311"},{"key":"bibr12-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1177\/1756285610374117"},{"volume-title":"Fatigue and Multiple Sclerosis: Evidence-Based Management Strategies for Fatigue in Multiple Sclerosis","year":"1998","author":"Guidelines MSCP","key":"bibr13-23982128231185290"},{"key":"bibr14-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1177\/1756285616634247"},{"key":"bibr15-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/124.5.962"},{"key":"bibr16-23982128231185290","doi-asserted-by":"publisher","DOI":"10.3310\/hta8090"},{"key":"bibr17-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211005588"},{"key":"bibr18-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419835077"},{"key":"bibr19-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.5.8.580"},{"key":"bibr20-23982128231185290","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.727586"},{"key":"bibr21-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-06022-x"},{"key":"bibr22-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12801"},{"key":"bibr23-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1177\/2055217319887987"},{"key":"bibr24-23982128231185290","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2021-0014"},{"key":"bibr25-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(05)70166-6"},{"key":"bibr26-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002441"},{"key":"bibr27-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014656"},{"key":"bibr28-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1177\/11795735211028781"},{"key":"bibr29-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250820"},{"key":"bibr30-23982128231185290","first-page":"348","volume":"88","author":"Ralf G","year":"2017","journal-title":"Neurology"},{"key":"bibr31-23982128231185290","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006"},{"key":"bibr32-23982128231185290","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_436_17"},{"key":"bibr33-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12083"},{"key":"bibr34-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01135-8"},{"key":"bibr35-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.154.11.1571"},{"key":"bibr36-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102521"},{"key":"bibr37-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513475723"},{"key":"bibr38-23982128231185290","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"}],"container-title":["Brain and Neuroscience Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23982128231185290","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23982128231185290","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23982128231185290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T02:26:32Z","timestamp":1740795992000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/23982128231185290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":38,"alternative-id":["10.1177\/23982128231185290"],"URL":"https:\/\/doi.org\/10.1177\/23982128231185290","relation":{},"ISSN":["2398-2128","2398-2128"],"issn-type":[{"type":"print","value":"2398-2128"},{"type":"electronic","value":"2398-2128"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"23982128231185290"}}